ReviewJournal of pharmaceutical health care and sciences2026
Practical and clinical significance of the pharmacist-led antimicrobial stewardship.
Review in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Packaged intervention targeting oral antimicrobials in Japanese tertiary care outpatient setting: a quasi-experimental study.JAC-antimicrobial resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) undermines clinical care. Thus, ensuring appropriate antimicrobial therapy is crucial in global and national AMR countermeasures. This narrative review aimed to summarize pharmacist-led antimicrobial stewardship interventions in Japan and discuss their practical and clinical significance across inpatient, outpatient, and community settings. In inpatient care, antimicrobial stewardship programs (ASPs), usually embedded within antimicrobial stewardship teams and supported by national policies and reimbursement incentives, have consistently reduced broad-spectrum antibiotic use (e.g., carbapenems). ASPs improve microbiological indicators such as Pseudomonas aeruginosa susceptibility while maintaining patient safety. The evidence of ASP efficiency spans large tertiary hospitals that consider post-prescription review with feedback and expanded prospective audit-and-feedback. In addition, small-to-medium hospitals that adopt pharmacist-led programs have demonstrated improved key process measures (culture acquisition, de-escalation, and duration of therapy), as well as optimized clinical outcomes in selected high-risk subgroups. Given that outpatient oral antibiotics account for a substantial proportion of total consumption, ASPs are increasingly being recognized as an essential approach. Reported pharmacist-led interventions include monitoring and feedback to high-prescription departments, regimen optimization based on susceptibility data, and dental outpatient programs that shift prescriptions from third-generation cephalosporins toward guideline-recommended penicillins. At the community level, regional educational outreach with surveillance feedback and peer-comparison approaches, as well as community pharmacy-based prescription optimization, have demonstrated meaningful shifts toward narrower-spectrum agents. Pharmacist-led ASPs in Japan have largely benefitted inpatients, whereas outpatient and community stewardship remains an essential frontier requiring enhanced implementation and rigorous assessment of patient-centered outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.